White AC Jr, Coyle CM, Rajshekhar V, et al. Diagnosis and treatment of neurocysticercosis: 2017 clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clin Infect Dis. 2018 Apr 3;66(8):e49-75.
Webb CM, White AC Jr. Update on the diagnosis and management of neurocysticercosis. Curr Infect Dis Rep. 2016 Dec;18(12):44.
Del Brutto OH, Nash TE, White AC Jr, et al. Revised diagnostic criteria for neurocysticercosis. J Neurol Sci. 2017 Jan 15;372:202-10.
Garcia HH, Gonzales I, Lescano AG, et al. Efficacy of combined antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: a double-blind, randomised controlled trial. Lancet Infect Dis. 2014 Aug;14(8):687-95.
1. Schantz PM, Kern P, Brunetti R. Echinococcus. In: Guerrant RL, Walker DH, Weller PF, eds. Tropical infectious diseases: principles, pathogens and practice. 1st ed. Oxford, UK: Churchill Livingstone; 2005:1304-26.
2. Wittner M, Tanowitz HB, White AC. Taenia and other tapeworms. In: Guerrant RL, Walker DH, Weller PF, eds. Tropical infectious diseases: principles, pathogens and practice. 1st ed. Oxford, UK: Churchill Livingstone; 2005:1327-40.
3. Hernández-Orts JS, Scholz T, Brabec J, et al. High morphological plasticity and global geographical distribution of the Pacific broad tapeworm Adenocephalus pacificus (syn. Diphyllobothrium pacificum): molecular and morphological survey. Acta Trop. 2015 Sep;149:168-78.
4. Garcia HH, del Brutto OH. Taenia solium cysticercosis. Inf Dis Clin North Am. 2000 Mar;14(1):97-119.
5. Verastegui M, Gilman RH, Garcia HH, et al. Prevalence of antibodies to unique Taenia solium onchosphere antigens in Taeniasis and human and porcine cysticercosis. Am J Trop Med Hyg. 2003 Oct;69(4):438-44.
6. Gonzalez AE, Garcia HH, Gilman RH, et al. Control of Taenia solium. Acta Trop. 2003 Jun;87(1):103-9.
7. Zoli A, Shey-Njila O, Assana E, et al. Regional status, epidemiology and impact of Taenia solium cysticercosis in Western and Central Africa. Acta Trop. 2003 Jun;87(1):35-42.
8. Braae UC, Thomas LF, Robertson LJ, et al. Epidemiology of Taenia saginata taeniosis/cysticercosis: a systematic review of the distribution in the Americas. Parasit Vectors. 2018 Sep 20;11(1):518.
9. O'Neal SE, Flecker RH. Hospitalization frequency and charges for neurocysticercosis, United States, 2003-2012. Emerg Infect Dis. 2015 Jun;21(6):969-76.
10. World Health Organization. Taeniasis/cysticercosis: fact sheet. Feb 2018 [internet publication].
11. Laranjo-González M, Devleesschauwer B, Trevisan C, et al. Epidemiology of taeniosis/cysticercosis in Europe, a systematic review: Western Europe. Parasit Vectors. 2017 Jul 21;10(1):349.
12. Scholz T, Garcia HH, Kuchta R, et al. Update on the human broad tapeworm (genus diphyllobothrium), including clinical relevance. Clin Microbiol Rev. 2009 Jan;22(1):146-60.
13. Khalil HM, el Shimi S, Sarwat MA, et al. Recent study of Hymenolepis nana infection in Egyptian children. J Egypt Soc Parasitol. 1991 Apr;21(1):293-300.
14. Aria HP. Biology of the tapeworm Hymenolepis diminuta. New York, NY: Academic Press; 1980.
15. Biswas H, Arora RR, Sehgal S. Epidemiology of Hymenolepis nana infections in a selected rural community. J Commun Dis. 1978;10(3):170-4.
16. Mason PR, Patterson BA. Epidemiology of Hymenolepis nana infections in primary school children in urban and rural communities in Zimbabwe. J Parasitol. 1994 Apr;80(2):245-50.
17. Del Brutto OH, Sotelo J, Roman GC. Neurocysticercosis: a clinical handbook. Lisse, The Netherlands: Swets and Zeitlinger; 1998.
18. Bandres JC, White AC Jr, Samo T, et al. Extraparenchymal neurocysticercosis: report of five cases and review of management. Clin Infect Dis. 1992 Nov;15(5):799-811.
19. Garcia HH, Wittner M, Coyle CM, et al. Cysticercosis. In: Guerrant RL, Walker DH, Weller PF, eds. Tropical infectious diseases: principles, pathogens and practice. 1st ed. Oxford, UK: Churchill Livingstone; 2005:1289-303.
20. Garcia HH, Gonzalez AE, Tsang VC, et al. Elimination of Taenia solium transmission in northern Peru. N Engl J Med. 2016 Jun 16;374(24):2335-44.
21. Di Lernia V, Ricci C, Albertini G. Skin eruption associated with Hymenolepis nana infection. Int J Dermatol. 2004 May;43(5):357-9.
22. Muehlenbachs A, Bhatnagar J, Agudelo CA, et al. Malignant transformation of Hymenolepis nana in a human host. N Engl J Med. 2015 Nov 5;373(19):1845-52.
23. Conn DB. Malignant transformation of Hymenolepis nana in a human host. N Engl J Med. 2016 Mar 31;374(13):1293-4.
24. Cuetter AC, Garcia-Bobadilla J, Guerra LG, et al. Neurocysticercosis: focus on intraventricular disease. Clin Infect Dis. 1997 Feb;24(2):157-64.
25. White AC Jr, Coyle CM, Rajshekhar V, et al. Diagnosis and treatment of neurocysticercosis: 2017 clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clin Infect Dis. 2018 Apr 3;66(8):e49-75.
26. Proaño-Navarez JV, Meza-Lucas A, Mata-Ruiz O, et al. Laboratory diagnosis of human neurocysticercosis: double-blind comparison of enzyme-linked immunosorbent assay and electroimmunotransfer blot assay. J Clin Microbiol Rev. 2002 Jun;40(6):2115-8.
27. Mejia R, Nutman TB. Evaluation and differential diagnosis of marked, persistent eosinophilia. Semin Hematol. 2012 Apr;49(2):149-59.
28. Groove D. A history of human helminthology. Wallingford, UK: CAB International; 1990.
29. WHO Informal Working Group. International classification of ultrasound images in cystic echinococcosis for application in clinical and field epidemiological settings. Acta Trop. 2003 Feb;85(2):253-61.
30. Webb CM, White AC Jr. Update on the diagnosis and management of neurocysticercosis. Curr Infect Dis Rep. 2016 Dec;18(12):44.
31. Garcia HH, Gilman R, Martinez M, et al. Cysticercosis as a major cause of epilepsy in Peru. Lancet. 1993 Jan 23;341(8839):197-200.
32. Del Brutto OH, Nash TE, White AC Jr, et al. Revised diagnostic criteria for neurocysticercosis. J Neurol Sci. 2017 Jan 15;372:202-10.
33. Carpio A, Fleury A, Romo ML, et al. New diagnostic criteria for neurocysticercosis: reliability and validity. Ann Neurol. 2016 Sep;80(3):434-42.
34. White AC Jr, Garcia HH. Updates on the management of neurocysticercosis. Curr Opin Infect Dis. 2018 Oct;31(5):377-82.
35. Centers for Disease Control and Prevention. Parasites - taeniasis: resources for health professionals. Jan 2013 [internet publication].
36. Baird RA, Wiebe S, Zunt JR, et al. Evidence-based guideline: treatment of parenchymal neurocysticercosis: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013 Apr 9;80(15):1424-9.
37. Otte WM, Singla M, Sander JW, et al. Drug therapy for solitary cysticercus granuloma: a systematic review and meta-analysis. Neurology. 2013 Jan 8;80(2):152-62.
38. García HH, Evans CA, Nash TE, et al. Current consensus guidelines for treatment of neurocysticercosis. Clin Microbiol Rev. 2002 Oct;15(4):747-56.
39. Proaňo JV, Madrazo I, Avelar F, et al. Medical treatment for neurocysticercosis characterized by giant subarachnoid cysts. N Engl J Med. 2001 Sep 20;345(12):879-85.
40. Mitre E, Talaat KR, Sperling MR, et al. Methotrexate as a corticosteroid-sparing agent in complicated neurocysticercosis. Clin Infect Dis. 2007 Feb 15;44(4):549-53.
41. Garcia HH, Lescano AG, Gonzales I, et al. Cysticidal efficacy of combined treatment with praziquantel and albendazole for parenchymal brain cysticercosis. Clin Infect Dis. 2016 Jun 1;62(11):1375-9.
42. Garcia HH, Gonzales I, Lescano AG, et al. Efficacy of combined antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: a double-blind, randomised controlled trial. Lancet Infect Dis. 2014 Aug;14(8):687-95.
43. Garcia HH, Gonzales I, Lescano AG, et al. Enhanced steroid dosing reduces seizures during antiparasitic treatment for cysticercosis and early after. Epilepsia. 2014 Sep;55(9):1452-9.
44. Koul PA, Singh AA, Ahanger AG, et al. Optimal duration of preoperative anti-helminthic therapy for pulmonary hydatid surgery. ANZ J Surg. 2010 May;80(5):354-7.
45. Khuroo MS, Wani NA, Javid G, et al. Percutaneous drainage compared with surgery for hepatic hydatid cysts. N Engl J Med. 1997 Sep 25;337(13):881-7.
46. Smego RA Jr, Bhatti S, Khaliq AA, et al. Percutaneous aspiration-injection-reaspiration drainage plus albendazole or mebendazole for hepatic cystic echinococcosis: a meta-analysis. Clin Infect Dis. 2003 Oct 15;37(8):1073-83.
47. The Medical Letter. Drugs for parasitic infections. New Rochelle, NY: The Medical Letter; 2007.
48. ClinicalTrials.gov. Phase I trial evaluating the safety and pharmacokinetics of oxfendazole (NCT02234570). Jan 2017 [internet publication].
使用此内容应接受我们的免责声明。
BMJ临床实践的持续改进离不开您的帮助和反馈。如果您发现任何功能问题和内容错误,或您对BMJ临床实践有任何疑问或建议,请您扫描右侧二维码并根据页面指导填写您的反馈和联系信息*。一旦您的建议在我们核实后被采纳,您将会收到一份小礼品。
如果您有紧急问题需要我们帮助,请您联系我们。
邮箱:bmjchina.support@bmj.com
电话:+86 10 64100686-612
*您的联系信息仅会用于我们与您确认反馈信息和礼品事宜。
BMJ临床实践官方反馈平台